GeneThera, Inc. (GTHR)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2022 | - USD | 100.0% |
| 2021 | -1 Million USD | -36.53% |
| 2020 | -735.33 Thousand USD | -0.2% |
| 2019 | -733.87 Thousand USD | 81.29% |
| 2018 | -3.92 Million USD | -547.43% |
| 2017 | -152.02 Thousand USD | 10.94% |
| 2016 | -98.85 Thousand USD | 24.51% |
| 2015 | -900.89 Thousand USD | -51.2% |
| 2014 | -595.84 Thousand USD | 45.05% |
| 2013 | -1.08 Million USD | 23.38% |
| 2012 | -1.77 Million USD | -27.5% |
| 2011 | -1.11 Million USD | -134.01% |
| 2010 | -474.34 Thousand USD | 50.54% |
| 2009 | -1.11 Million USD | 50.02% |
| 2008 | -1.91 Million USD | -149.37% |
| 2007 | -753.49 Thousand USD | 44.25% |
| 2006 | -1.4 Million USD | 53.49% |
| 2005 | -3.25 Million USD | 5.21% |
| 2004 | -4.37 Million USD | -18.98% |
| 2003 | -2.53 Million USD | -213.64% |
| 2002 | -598.88 Thousand USD | -253.57% |
| 2001 | -480.59 Thousand USD | -1206.92% |
| 2000 | -277.61 Thousand USD | 93.62% |
| 1999 | -284.64 Thousand USD | -281.49% |
| 1998 | -74.61 Thousand USD | -148.71% |
| 1997 | -30 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q1 | - USD | 0.0% |
| 2023 Q3 | - USD | 0.0% |
| 2023 Q2 | - USD | 0.0% |
| 2022 Q3 | -123.69 Thousand USD | 15.63% |
| 2022 Q1 | -130.86 Thousand USD | 51.79% |
| 2022 FY | - USD | 100.0% |
| 2022 Q4 | - USD | 100.0% |
| 2022 Q2 | -146.61 Thousand USD | -12.03% |
| 2021 Q3 | -242.54 Thousand USD | 14.91% |
| 2021 Q2 | -285.05 Thousand USD | -40.23% |
| 2021 Q4 | -271.46 Thousand USD | -11.92% |
| 2021 Q1 | -203.27 Thousand USD | -55.41% |
| 2021 FY | - USD | -36.53% |
| 2020 Q1 | -140.38 Thousand USD | 40.96% |
| 2020 Q2 | -192.74 Thousand USD | -37.29% |
| 2020 Q3 | -271.4 Thousand USD | -40.81% |
| 2020 Q4 | -130.8 Thousand USD | 51.8% |
| 2020 FY | - USD | -0.2% |
| 2019 Q3 | -203 Thousand USD | -49.08% |
| 2019 Q2 | -136.17 Thousand USD | 13.21% |
| 2019 Q1 | -156.9 Thousand USD | 94.97% |
| 2019 Q4 | -237.78 Thousand USD | -17.13% |
| 2019 FY | - USD | 81.29% |
| 2018 Q3 | -312.16 Thousand USD | -0.77% |
| 2018 Q1 | -200.78 Thousand USD | -47.31% |
| 2018 FY | - USD | -547.43% |
| 2018 Q4 | -3.11 Million USD | -899.17% |
| 2018 Q2 | -309.77 Thousand USD | -54.28% |
| 2017 Q3 | -109.98 Thousand USD | 4.24% |
| 2017 FY | - USD | 10.94% |
| 2017 Q1 | -244.56 Thousand USD | -133.8% |
| 2017 Q2 | -114.85 Thousand USD | 53.04% |
| 2017 Q4 | -136.29 Thousand USD | -23.92% |
| 2016 Q1 | -260.75 Thousand USD | -29.65% |
| 2016 FY | - USD | 24.51% |
| 2016 Q4 | -104.6 Thousand USD | 15.2% |
| 2016 Q3 | -123.35 Thousand USD | 35.54% |
| 2016 Q2 | -191.35 Thousand USD | 26.62% |
| 2015 FY | - USD | -51.2% |
| 2015 Q1 | -348.8 Thousand USD | -225.22% |
| 2015 Q2 | -147.45 Thousand USD | 57.73% |
| 2015 Q3 | -203.28 Thousand USD | -37.87% |
| 2015 Q4 | -201.12 Thousand USD | 1.06% |
| 2014 Q3 | -115.35 Thousand USD | 45.25% |
| 2014 Q1 | -162.56 Thousand USD | 11.83% |
| 2014 FY | - USD | 45.05% |
| 2014 Q4 | -107.25 Thousand USD | 7.02% |
| 2014 Q2 | -210.67 Thousand USD | -29.6% |
| 2013 Q2 | -278.63 Thousand USD | -1.79% |
| 2013 FY | - USD | 23.38% |
| 2013 Q4 | -184.36 Thousand USD | 47.36% |
| 2013 Q3 | -350.22 Thousand USD | -25.69% |
| 2013 Q1 | -273.74 Thousand USD | 18.51% |
| 2012 Q1 | -512.78 Thousand USD | -169.65% |
| 2012 Q2 | -335.46 Thousand USD | 34.58% |
| 2012 FY | - USD | -27.5% |
| 2012 Q4 | -335.94 Thousand USD | -45.55% |
| 2012 Q3 | -230.81 Thousand USD | 31.2% |
| 2011 FY | - USD | -134.01% |
| 2011 Q1 | -139.1 Thousand USD | 20.07% |
| 2011 Q4 | 736.18 Thousand USD | 148.25% |
| 2011 Q2 | -186 Thousand USD | -33.72% |
| 2011 Q3 | -1.52 Million USD | -720.31% |
| 2010 FY | - USD | 50.54% |
| 2010 Q1 | -106.38 Thousand USD | -86.14% |
| 2010 Q2 | -87.65 Thousand USD | 17.61% |
| 2010 Q4 | -174.02 Thousand USD | -63.73% |
| 2010 Q3 | -106.28 Thousand USD | -21.26% |
| 2009 Q1 | -298.12 Thousand USD | -119.67% |
| 2009 Q3 | -298.48 Thousand USD | -6.47% |
| 2009 Q2 | -280.34 Thousand USD | 5.96% |
| 2009 Q4 | -57.15 Thousand USD | 80.85% |
| 2009 FY | - USD | 50.02% |
| 2008 Q4 | 1.51 Million USD | 148.86% |
| 2008 Q2 | -140.63 Thousand USD | 18.2% |
| 2008 Q1 | -171.92 Thousand USD | -40.78% |
| 2008 Q3 | -3.1 Million USD | -2105.56% |
| 2008 FY | - USD | -149.37% |
| 2007 Q1 | -201.5 Thousand USD | 64.24% |
| 2007 FY | - USD | 44.25% |
| 2007 Q4 | -122.12 Thousand USD | 6.57% |
| 2007 Q3 | -130.71 Thousand USD | 60.58% |
| 2007 Q2 | -331.59 Thousand USD | -64.56% |
| 2006 Q3 | -471.44 Thousand USD | -32.17% |
| 2006 Q4 | -563.52 Thousand USD | -19.53% |
| 2006 FY | - USD | 53.49% |
| 2006 Q1 | -132.39 Thousand USD | 56.53% |
| 2006 Q2 | -356.69 Thousand USD | -169.43% |
| 2005 FY | - USD | 5.21% |
| 2005 Q1 | -2.2 Million USD | -117.19% |
| 2005 Q2 | -277.69 Thousand USD | 87.38% |
| 2005 Q3 | -236.71 Thousand USD | 14.76% |
| 2005 Q4 | -304.54 Thousand USD | -28.66% |
| 2004 Q4 | 12.8 Million USD | 5209.4% |
| 2004 Q3 | -250.58 Thousand USD | 98.34% |
| 2004 Q2 | -15.09 Million USD | -2589.4% |
| 2004 Q1 | -561.35 Thousand USD | 74.44% |
| 2004 FY | - USD | -18.98% |
| 2003 Q1 | -110.77 Thousand USD | 64.34% |
| 2003 FY | - USD | -213.64% |
| 2003 Q4 | -2.04 Million USD | -1092.17% |
| 2003 Q3 | -184.24 Thousand USD | -10.3% |
| 2003 Q2 | -167.04 Thousand USD | -198.96% |
| 2002 Q4 | -156.68 Thousand USD | -15.6% |
| 2002 FY | - USD | -253.57% |
| 2002 Q1 | -262.97 Thousand USD | -11.2% |
| 2002 Q2 | -311.36 Thousand USD | 11.28% |
| 2002 Q3 | -136.07 Thousand USD | 41.97% |
| 2001 FY | - USD | -1206.92% |
| 2001 Q4 | -272.9 Thousand USD | -298.15% |
| 2001 Q3 | -59.46 Thousand USD | 68.22% |
| 2001 Q2 | -119.18 Thousand USD | -503.86% |
| 2001 Q1 | -30.98 Thousand USD | -122.47% |
| 2000 Q1 | -51.45 Thousand USD | 80.21% |
| 2000 Q2 | -69.34 Thousand USD | -34.77% |
| 2000 Q3 | -13.43 Thousand USD | 80.63% |
| 2000 Q4 | 137.85 Thousand USD | 1126.4% |
| 2000 FY | - USD | 93.62% |
| 1999 Q3 | 90 Thousand USD | 0.0% |
| 1999 Q1 | -50 Thousand USD | 0.0% |
| 1999 FY | - USD | -281.49% |
| 1999 Q4 | -260 Thousand USD | -388.89% |
| 1999 Q2 | - USD | 100.0% |
| 1998 FY | - USD | -148.71% |
| 1998 Q4 | - USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 100.0% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 100.0% |
| SQZ Biotechnologies Company | -64.14 Million USD | 100.0% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 100.0% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 100.0% |
| Mesoblast Limited | -62.38 Million USD | 100.0% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 100.0% |
| Genus plc | 73.7 Million USD | 100.0% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 100.0% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 100.0% |
| Marizyme, Inc. | -34.28 Million USD | 100.0% |
| ContraFect Corporation | -64.99 Million USD | 100.0% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 100.0% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 100.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | NaN% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 100.0% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 100.0% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 100.0% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | 100.0% |
| Accustem Sciences Inc. | -3.74 Million USD | 100.0% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 100.0% |
| EV Biologics, Inc. | -1.26 Million USD | 100.0% |
| Q BioMed Inc. | -617.62 Thousand USD | 100.0% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 100.0% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 100.0% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 100.0% |
| Biomind Labs Inc. | -1.03 Million USD | 100.0% |
| TetraLogic Pharmaceuticals Corporation | - USD | NaN% |
| Pharming Group N.V. | 9.87 Million USD | 100.0% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 100.0% |
| Skye Bioscience, Inc. | -13.54 Million USD | 100.0% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 100.0% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 100.0% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 100.0% |
| IMV Inc. | -35.52 Million USD | 100.0% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 100.0% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 100.0% |
| GB Sciences, Inc. | -1.41 Million USD | 100.0% |
| Alpha Cognition Inc. | -9.7 Million USD | 100.0% |
| HST Global, Inc. | -5303.00 USD | 100.0% |
| CSL Limited | 4.78 Billion USD | 100.0% |
| Halberd Corporation | -74.27 Thousand USD | 100.0% |
| Enzolytics Inc. | -2.12 Million USD | 100.0% |
| Resverlogix Corp. | -11.74 Million USD | 100.0% |
| Affymax, Inc. | -14.29 Million USD | 100.0% |
| SYBLEU INC | -141.57 Thousand USD | 100.0% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 100.0% |
| argenx SE | -216.02 Million USD | 100.0% |
| MetaStat, Inc. | - USD | NaN% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 100.0% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 100.0% |
| Arno Therapeutics, Inc. | - USD | NaN% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 100.0% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 100.0% |
| AVAX Technologies, Inc. | -6.11 Million USD | 100.0% |
| Zenith Capital Corp. | -8.6 Million USD | 100.0% |
| Genscript Biotech Corporation | -248.71 Million USD | 100.0% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 100.0% |
| Anthera Pharmaceuticals, Inc. | - USD | NaN% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 100.0% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | 100.0% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 100.0% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 100.0% |
| Adynxx, Inc. | - USD | NaN% |
| Helix BioMedix, Inc. | -1.04 Million USD | 100.0% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 100.0% |
| VitaSpring Biomedical Co. Ltd. | - USD | NaN% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 100.0% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 100.0% |
| BioStem Technologies, Inc. | -7.55 Million USD | 100.0% |
| ONE Bio Corp. | 13.61 Million USD | 100.0% |
| Reve Technologies, Inc. | -181.08 Thousand USD | 100.0% |
| Burzynski Research Institute, Inc. | - USD | NaN% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 100.0% |
| Agentix Corp. | -1.37 Million USD | 100.0% |
| LadRx Corporation | 412.28 Thousand USD | 100.0% |
| Cell Source, Inc. | -4.27 Million USD | 100.0% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | 100.0% |
| Regen BioPharma, Inc. | 1.46 Million USD | 100.0% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 100.0% |
| NovAccess Global Inc. | -1.03 Million USD | 100.0% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 100.0% |
| Itoco Inc. | -1.86 Million USD | 100.0% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | 100.0% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 100.0% |
| Kadimastem Ltd | -2.62 Million USD | 100.0% |
| Oncology Pharma Inc. | - USD | NaN% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | 100.0% |
| CytoDyn Inc. | -18.02 Million USD | 100.0% |
| Claritas Pharmaceuticals, Inc. | - USD | NaN% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | 100.0% |
| Mobile Lads Corp. | -2.24 Million USD | 100.0% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | 100.0% |
| Qrons Inc. | -40.08 Thousand USD | 100.0% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | 100.0% |
| Advanced Proteome Therapeutics Corporation | - USD | NaN% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 100.0% |
| Rebus Holdings, Inc. | -951 Thousand USD | 100.0% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 100.0% |
| International Stem Cell Corporation | 202 Thousand USD | 100.0% |
| Bioxytran, Inc. | -3.82 Million USD | 100.0% |
| GlobeImmune, Inc. | - USD | NaN% |
| Predictive Technology Group, Inc. | - USD | NaN% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 100.0% |
| Cardax, Inc. | - USD | NaN% |
| VG Life Sciences Inc. | -2.46 Million USD | 100.0% |
| Kaleido Biosciences, Inc. | - USD | NaN% |
| Advaxis, Inc. | -35.86 Million USD | 100.0% |
| Adhera Therapeutics, Inc. | - USD | NaN% |
| RenovaCare, Inc. | - USD | NaN% |
| Regnum Corp. | -45 Thousand USD | 100.0% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 100.0% |
| Neutra Corp. | -181.24 Thousand USD | 100.0% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 100.0% |
| PureTech Health plc | -11.62 Million USD | 100.0% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 100.0% |
| IXICO plc | -707 Thousand USD | 100.0% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 100.0% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 100.0% |
| CSL Limited | 4.73 Billion USD | 100.0% |
| Cellectis S.A. | -92.63 Million USD | 100.0% |